In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: U.S. Physical Therapy’s current price exceeds the weighted fair value by 17.5%, indicating potential overvaluation with notable downside risk (83.3% scenarios below price). Valuation methods diverge widely, from conservative DCF ($36.44) to optimistic EV/EBITDA ($158.02), reflecting high volatility (58.29% coefficient of variation). Financial health scores reveal poor profitability, efficiency, and growth, signaling elevated investment risk.